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SUMMARY
In this work, the effect of vaccination of a newly described
Leishmania infantum antigenic protein has been studied in
BALB/c mice infected with this parasite species. The LiHyD
protein was characterized after a proteomic screening per-
formed with the sera from dogs suffering visceral leishmani-
asis (VL). Its recombinant version was expressed, purified
and administered to BALB/c mice in combination with sapo-
nin. As a result of vaccination and 10 weeks after challenge
using an infective dose of L. infantum stationary promastig-
otes, vaccinated mice showed lower parasite burdens in dif-
ferent organs (liver, spleen, bone marrow and footpads’
draining lymph nodes) than mice inoculated with the adju-
vant alone or the vaccine diluent. Protected mice showed
anti-Leishmania IgG2a antibodies and a predominant IL-
12-driven IFN-c production (mainly produced by CD4+ T
cells) against parasite proteins, whereas unprotected controls
showed anti-Leishmania IgG1 antibodies and parasite-
mediated IL-4 and IL-10 responses. Vaccinated mice showed
an anti-LiHyD IgG2a humoral response, and their spleen
cells were able to secrete LiHyD-specific IFN-c, IL-12 and
GM-CSF cytokines before and after infection. The protec-
tion was correlated with the Leishmania-specific production
on nitric oxide. Altogether, the results indicate that the new
LiHyD protein could be considered in vaccine formulations
against VL.
Keywords BALB/c mice, experimental vaccine, hypothetical
protein, Leishmania infantum, saponin
INTRODUCTION
Visceral leishmaniasis (VL) caused by Leishmania donovani
and L. infantum/L. chagasi is an important neglected dis-
ease in the world (1). About 350 million people are at risk
of contracting the infection in 98 countries, and
02–05 million of new cases of VL are registered annually
(1, 2). The treatment of this disease is yet mostly based on
the parenteral administration of pentavalent antimonials.
However, increased parasite resistance and side effects reg-
istered in the patients have been the important problems
(3, 4). Alternative drugs, such as amphotericin B and its
liposomal formulations, pentamidine and miltefosine, have
showed encouraging results; however, their toxicity, the
increase of parasite resistance and/or high cost had limited
their use (5–7). A VL elimination campaign has been initi-
ated around the world, which will focus on vector control,
early diagnosis and drug treatment strategies (8, 9). How-
ever, it is presumed that a vaccine will be required for
successful elimination of the disease.
The development of a type 1 T helper (Th)-mediated
immunity to prevent leishmaniasis has inspired the devel-
opment of prophylactic vaccination against the disease,
but few have progressed beyond the experimental stage
using mice models for cutaneous and VL (10–14). The
induction of specific CD4+ Th1 cells against parasite pro-
teins is crucial in controlling the infection caused by Leish-
mania spp. Both T CD4+ and CD8+ cells are the major
weapons for an anti-Leishmania immune response, and
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they play a crucial role through the IL-2 and IFN-c pro-
duction. These cytokines activate the effector functions of
macrophages, inducing the production of nitric oxide
(NO), a molecule able to destroy the intracellular amastig-
otes (15, 16). Progression of the disease is associated with
the induction of parasite-specific TGF-b-, IL-10- and IL-
13-mediated responses (17–19). In addition, control of the
IL-4-mediated Th2 humoral response against Leishmania
commonly enhances vaccine-induced protection by indi-
rectly increasing IFN-c production by T cells (20–23).
The search for new targets to compose a vaccine is an
important strategy for leishmaniasis control, mainly when
employing proteins that are recognized by patients’ sera,
indicating that these antigens are present in the intracellu-
lar stages of the parasites and that they are able to inter-
act with the host immune system. In recent decades, most
of the studies evaluating vaccines for leishmaniasis have
focused on Leishmania spp. proteins possessing orthologue
forms in other protozoan or mammalian species (16, 24–
28). As a result of the application of proteomics for the
search of new antigens, some proteins considered in the
database as hypothetical (because of their lack of sequence
similarity to previous described proteins) were character-
ized. As they were recognized by sera of mammalian hosts
infected by cutaneous or viscerotropic Leishmania species,
they have emerged as putative new vaccine candidates.
Besides its antigenicity, these proteins do not exhibit a
high degree of sequence conservation with any host coun-
terparts, decreasing the possibility to induce cross-reactive
responses against the host.
We have designed a study to evaluate a new vaccine
candidate, a Leishmania spp.-specific hypothetical protein
namely LiHyD. The effects of the administration of the
protein obtained as a recombinant protein (rLiHyD) in
BALB/c mice (combined with saponin) in VL evolution
due to L. infantum infection have been studied. This pro-
tein was selected for the analysis, because of its reactivity
with sera from dogs with active VL (29). In addition, it is
conserved among different Leishmania species, but it is
not present in other trypanosomatids or in mammalian
species. The decrease in L. infantum infection progression
and the immune correlate with protection in vaccinated
mice is discussed, presenting the LiHyD hypothetical pro-
tein associated with Th1-type adjuvants as a formulation
able to protect against VL.
MATERIALS AND METHODS
Ethics statement
This study was approved by Committee on the Ethical
Handling of Research Animals from Federal University of
Minas Gerais (UFMG), Belo Horizonte, Minas Gerais,
Brazil, under the protocol number 043/2011.
Mice and parasite
Female BALB/c mice (8 weeks of age) obtained from the
breeding facilities of the Department of Biochemistry and
Immunology, Institute of Biological Sciences, UFMG,
were maintained under specific pathogen-free conditions.
Experiments were carried out using the L. infantum
(MHOM/BR/1970/BH46) strain. Parasites were grown at
24°C in Schneider’s medium (Sigma, St. Louis, MO,
USA), supplemented with 10% heat-inactivated foetal
bovine serum (FBS, Sigma), 20 mM L-glutamine, 200 U/
mL penicillin and 100 lg/mL streptomycin, at pH 74.
The soluble L. infantum antigenic extract (SLA) was pre-
pared from 1 9 1010 stationary-phase promastigote cul-
tures (5–7 days old), as described (30).
Obtaining the Leishmania-specific hypothetical protein,
LiHyD
The LiHyD (LinJ.333150) nucleotide and amino acid
sequences used in this study were obtained from Tri-
TrypDB (http://tritrypdb.org). The local alignment of the
LiHyD sequence against the available complete genomes
of other organisms was performed by BLAST. For obtain-
ing the recombinant protein (rLiHyD), its coding region
was amplified by PCR using genomic L. infantum DNA
(as Leishmania protein genes lacks introns) and the next
primers: forward (5’-GGATCCATGCAGATGCAAGG
CAACATG-3’) and reverse (5’-AAGCTTATTGTTGCCG
CATACTTGG-3’). The coding region was cloned into the
pGEM-T Vector Systems (Promega, Madison, WI, USA)
and double stranded sequenced. After the DNA insert was
obtained by a BamHI and HindIII double digestion (tak-
ing advance of the corresponding cut sites included in the
primers [underlined]) and transferred to the same cut sites
of the pQE30 plasmid (Qiagen, Hilden, Germany).
Recombinant plasmid was transformed into Escherichia
coli M15 strain where the overexpression of the recombi-
nant protein was performed by adding 10 mM IPTG (iso-
propyl-b-D-thiogalactopyranoside, Promega, Montreal,
Canada), for 3 h at 37°C. For protein purification, cells
were lysed by a homogenizer after five passages through
the apparatus. The product was centrifuged at 13 000 9 g
for 20 min at 4°C. The rLiHyD protein, containing a tag
of 69 residues of histidine fused at its N-terminal region,
was purified under nondenaturing conditions, using a
5 mL His-Trap column (GE Healthcare Bio-Sciences,
Pittsburgh, USA), attached to an FPLC (GE Healthcare
Life Science) system. The recombinant protein was dial-
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ysed using saline as a buffer. After dialysis, rLiHyD was
passed through a polymyxin–agarose column (Sigma), to
remove residual endotoxin content (<10 ng of LPS per
1 mg of recombinant protein, measured by the Quantita-
tive Chromogenic Limulus Amebocyte Assay QCL-1000;
BioWhittaker, Walkersville, USA). In addition, the purity
of the recombinant protein was checked by a one-dimen-
sional 10% SDS-PAGE as described below.
SDS-PAGE and immunoblotting analysis
To analyse the purity of the recombinant LiHyD protein,
bacterial total extracts containing the expressed protein and
the protein obtained at the end of the purification process
(10 lg each sample) were submitted to a 10% SDS-PAGE.
Gels were stained with Coomassie blue. Similar gels contain-
ing the purified were blotted onto a nitrocellulose mem-
brane (02 lm pore size, Sigma). Membranes were blocked
with PBS-T (phosphate-buffered saline plus Tween-20
005%) plus 5% BSA for 1 h and were independently incu-
bated for 2 h with two pools of sera samples obtained from
naive mice (n = 8) or L. infantum-chronically infected
BALB/c mice (1 : 100 dilution in PBS-T solution). VL ani-
mals (n = 8) were subcutaneously infected by 1 9 107 sta-
tionary promastigotes of L. infantum, and sera were
collected at week 10 after infection. As secondary antibody,
blots were incubated with peroxidase-conjugated
anti-mouse IgG (1 : 10 000; Sigma) for 2 h. Reactions were
revealed by adding chloronaphthol, diaminobenzidine and
H2O2, and stopped by adding distilled water.
Immunization and challenge infection
For immunization, three groups (n = 8 animals per group)
were made. Vaccinated group were inoculated subcuta-
neously in their left hind footpad with 25 lg of rLiHyD
associated with 25 lg of saponin (Quillaja saponaria bark
saponin, Sigma). Control mice were similarly inoculated
with the adjuvant (25 lg of saponin) or the vaccine diluent
(PBS). Three doses were administered at 2-week intervals.
Four weeks after the final immunization, animals (n = 4
per group) were euthanized to analyse the immune response
elicited by vaccination. At the same time, the remaining
animals (n = 4, per group) were subcutaneously infected in
the right hind footpad with 1 9 107 stationary-phase pro-
mastigotes of L. infantum. To determine parasite burden
and to evaluate the immune response post-challenge, mice
were euthanized at week 10 after infection. Vaccination
experiments were repeated and presented similar results.
Data shown in this study represent the mean  standard
deviation of the individual data pooled from two indepen-
dent experiments, which presented similar results.
Estimation of parasite load
Single-cell suspensions of the spleen, liver, draining lymph
nodes (dLN) and bone marrow (BM) from mice were
independently prepared for parasite quantification, follow-
ing a limiting-dilution protocol (30). Briefly, the organs
were weighed and homogenized using a glass tissue grin-
der in sterile PBS. Tissue debris were removed by centrifu-
gation at 150 9 g, and cells were concentrated by
centrifugation at 2000 9 g. Sediment cells were suspended
in 1 mL of supplemented Schneider’s insect medium (pre-
pared as depicted above, but using 20% FBS). Ten-fold
serial dilutions (from 101 to 1012) were made in the
same medium using 96-well flat-bottom microtiter plates
(Nunc, Nunclon, Roskilde, Denmark). Each individual
sample was plated in triplicate, and parasites’ presence
was analysed by microscopy after 7 days of culturing at
24°C. Pipette tips were discarded after each dilution step
to avoid carrying adhered parasites from one well to
another. Results are expressed as the log of the titre (i.e.
the dilution corresponding to the last positive well)
adjusted per milligram of tissue.
Cytokine and nitrite production
Splenocyte cultures were established from individual mice
(n = 4, per group) at the time of the two described sacri-
fices. For this, single-cell preparations were plated in
duplicate in 24-well plates (Nunc) at 5 9 106 cells per
mL. Cells were incubated in complete DMEM medium
(DMEM supplemented with 10% heat-inactivated foetal
bovine serum, 20 mM L-glutamine, 200 U/mL penicillin
and 100 lg/mL streptomycin) in the absence (negative
control) or in the presence of rLiHyD protein (20 lg/mL)
or L. infantum SLA (25 lg/mL), at 37°C in 5% CO2 for
48 h. IFN-c, IL-4, IL-10, IL-12 and GM-CSF levels were
assessed in the supernatants by a sandwich ELISA kit
(BD OptEIA TM set mouse IFN-c (AN-18), IL-4, IL-10,
IL-12 and GM-CSF; Pharmingen, San Diego, CA,
USA) following manufacturer’s instructions. When indi-
cated, and in order to block IL-12-, CD4+- and CD8+-
mediated T-cell cytokine release, spleen cells of mice
vaccinated with rLiHyD plus saponin and challenged with
L. infantum were in vitro stimulated with SLA (25 lg/
mL), in the absence or in the presence of 5 lg/mL of
monoclonal antibodies (mAb) against mouse IL-12
(C178), CD4 (GK 15) or CD8 (53-67). Appropriate iso-
type-matched controls (rat IgG2a (R35-95) and rat IgG2b
(95-1)) were employed in the assays. Antibodies (no azide/
low endotoxinTM) were purchased from BD (Pharmin-
gen). The nitrite production in the cultures supernatant
was assessed by the Griess reaction (31) in the
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supernatants of spleen cells cultures established from indi-
vidual infected mice (n = 4, per group), and stimulated
and cultured as above. Data were expressed as lM per
5 9 106 cells.
Evaluation of the antibody production
The humoral response was evaluated by collecting sera
samples of the animals (n = 4, per group) after the last
immunization and before infection (4 weeks after last
doses), as well as at the 10th week after challenge. For
this, The LiHyD- and L. infantum SLA-specific IgG1 and
IgG2a isotypes levels were measured by an ELISA tech-
nique, as described (12). Recombinant protein was
employed at 5 lg/mL, and SLA was assayed at 10 lg/mL
(100 lL per well). The sera samples were diluted at
1 : 100, and the anti-mouse IgG1 and IgG2a horseradish
peroxidase-conjugated antibodies (Sigma-Aldrich) were
used in a 1 : 5000 dilution.
Statistical analysis
The results were processed using MICROSOFT EXCEL (version
10.0) or GRAPHPAD PRISMTM (version 6.0 for Windows). The
one-way analysis of variance (ANOVA), followed by Bonfer-
roni’s post-test, was used for multiple comparisons
between the groups. Differences were considered signifi-
cant when P < 005. As indicated above, individual data
from two different experiments were employed for the sta-
tistical analysis.
RESULTS
Expression, purification and antigenicity of the rLiHyD
To analyse the immunological properties of the rLiHyD
protein, the recombinant version of the protein was over-
expressed E. coli (Figure 1a, lane 2) and purified by affin-
ity chromatography (Lane 1A, lane 3, black arrow). A
band of 360 kDa, molecular weight expected from its pri-
mary structure, was observed in a Coomassie-stained 10%
SDS-PAGE gel (Figure 1a). Next, a Western blot of the
purified protein was incubated with sera samples obtained
from na€ıve BALB/c mice or sera from the same animals
but chronically infected with L. infantum. Results shown
in Figure 1(b) demonstrate that the purified protein was
recognized only by the sera from the infected mice (lane 3,
black arrow).
Figure 1 Antigenicity of the purified recombinant LiHyD protein. Analysis of the purification process is shown in (a). Molecular weight
markers (lane 1), 10 lg of total bacterial cultures expressing the rLiHyD protein (lane 2) and protein purified by affinity chromatography
(lane 3) were electrophoresed on a SDS-PAGE 10% gel. Coomassie staining of the gel is shown. In (b), similar gels loaded with molecular
weight markers (lane 1) and 10 lg of the LiHyD purified protein (lanes 2 and 3) were electrophoresed and blotted onto a nitrocellulose
membrane. Blots were incubated with pools of sera samples (n = 8 each group) from noninfected (lane 2) or chronically Leishmania
infantum-infected mice (lane 3), and revealed with chloronaphthol. A scan from the blots is shown. Black arrows label the position of the
rLiHyD protein in gels and blots.
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Protective efficacy of a vaccine composed by rLiHyD
plus saponin against L. infantum
To study the prophylactic properties of the rLiHyD pro-
tein, a vaccination–infection experiment was performed.
For that purpose, a group of mice was immunized with
the recombinant protein administered in combination
with saponin. Two control groups were performed: mice
inoculated with the same dose of saponin and mice inoc-
ulated with the vaccine diluent. A comparative analysis
of the parasite burdens found in the spleen, liver, dLN
and BM of the animals from the three groups was per-
formed 10 weeks after a L. infantum challenge, performed
subcutaneously in the footpads. It was observed that vac-
cinated mice presented significant reductions (between
4-log and 5-log) in the parasite load in the spleen (Fig-
ure 2a), liver (Figure 2b), dLN (Figure 2c) and BM (Fig-
ure 2d) when compared to both, saline and saponin
groups.
The immune response generated in the animals against
the parasite total proteins was analysed to compare the
post-infection immune parameters found in the three
groups of mice. Ten weeks after infection, vaccinated
mice had a Th1 profile against a preparation of soluble
leishmanial antigen (SLA). Thus, following in vitro stim-
ulation with L. infantum SLA, spleen cells from vacci-
nated and infected mice produced higher levels of IFN-
c, IL-12 and GM-CSF, than those secreted by spleen
cells from control mice groups (Figure 3a). As a corre-
late of disease progression, spleen cells from saline and
saponin inoculated mice produced predominant IL-4 and
IL-10 cytokine responses (Figure 3a). To evaluate the
involvement of CD4+ and CD8+ T cells and the depen-
dence of IL-12 in the parasite-specific IFN-c production
found in protected mice, their spleen cells were stimu-
lated with SLA in the absence or presence of anti-IL-12,
anti-CD4 or anti-CD8 monoclonal antibodies (Fig-
ure 3b). IFN-c production was significantly inhibited
when the three antibodies were employed. The highest
inhibition was obtained when the IL-12 blocking anti-
body was used, implicating to this cytokine in the para-
site-specific IFN-c response found in the protected mice.
Higher decrease was found after anti-CD4 treatment
than inhibiting the stimulation of CD8+ T cells with
monoclonal antibodies. These data were indicating that a
predominant Th1 response was found against the para-
site after infection in the protected mice. This finding
correlates with the presence of a predominant IgG2 par-
asite-specific humoral response after infection in rLiHyD
plus saponin vaccinated mice, in opposition to control
groups, having a predominant IgG1 humoral response
against SLA (Figure 4).
Figure 2 Protection of BALB/c mice vaccinated with rLiHyD plus saponin against Leishmania infantum infection. Mice inoculated with
saline, with saponin or with rLiHyD plus saponin (n = 4, per group) were subcutaneously challenged with 1 9 107 stationary-phase
promastigotes of L. infantum. The number of parasites in the liver (a), spleen (b), bone marrow (c) and paws’ draining lymph nodes (d)
was measured, 10 weeks after challenge, by a limiting-dilution technique. Mean  standard deviation (SD) in each group is shown. (a)
indicates statistically significant difference in relation to the saline group (P < 0001). (b) indicates statistically significant difference in
relation to the saponin group (P < 0001). Data shown in this figure represent the mean  standard deviation of two independent
experiments.
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rLiHyD-specific cellular and humoral response elicited
by immunization using rLiHyD plus saponin before and
after challenge infection
Next, the immune response elicited against the parasite anti-
gen contained in the vaccine was studied. For that, the pro-
duction of cytokines in the supernatants of spleen cells
cultures stimulated with rLiHyD was analysed before and
10 weeks after challenge infection (Figure 5). Before chal-
lenge, it was observed that spleen cells derived from mice
vaccinated with rLiHyD plus saponin produced higher
levels of rLiHyD-specific IFN-c, IL-12 and GM-CSF
cytokines, than those secreted by spleen cells from control
groups (Figure 5a). In contrast, no production LiHyD-
derived IL-4 and IL-10 could be observed in any experimen-
tal group. Mice that were immunized and lately challenged
with L. infantum maintained the Th1 profile after infection,
as their spleen cells cultures produced similar level of rLi-
HyD-specific cytokines than those secreted by spleen cells
from vaccinated but uninfected mice (Figure 5b).
Evaluating the rLiHyD-specific humoral response in the
vaccinated and/or infected animals (Figure 6), it was
observed that before (Figure 6a) and after (Figure 6b)
challenge, mice vaccinated with rLiHyD plus saponin pre-
sented higher levels of anti-rLiHyD-specific IgG1 and
IgG2a isotype antibodies than the saline and saponin
groups. The higher reactivity of the IgG2a antibodies
found in the sera from vaccinated animals against the rLi-
HyD protein correlated with the Th1 cellular response
determined by cytokine analysis. Although similar profiles
were found for the humoral response before and after
infection, the higher reactivity found post-challenge (com-
paring data from panel A and data shown in panel B; Fig-
ure 6) was indicating that the infection was able to boost
the immune response elicited by vaccination, without
changing its quality.
Analysis of the macrophage effector capacities after
infection
It is well documented that macrophages stimulated by
IFN-c are able to activate NO synthesis to destroy the
Figure 3 Cellular response against parasite proteins after
Leishmania infantum challenge. Single spleen cells from mice that
received saline or were inoculated with saponin or rLiHyD plus
saponin (n = 4, per group) and were infected with L. infantum
were collected, and independently cultured without stimulus
(medium; negative control) or in vitro stimulated with SLA
(25 lg/mL) for 48 h at 37°C in 5% CO2. IFN-c, IL-12, GM-CSF,
IL-4, and IL-10 levels were measured by ELISA in the culture
supernatants (panel a). (a) indicates statistically significant
increase in relation to the saline group (P < 0001). (b) indicates
statistically significant increase in relation to the saponin group
(P < 0001). (c) indicates statistically significant increase in
relation to the rLiHyD/saponin group (P < 0001). Also, spleen
cells from mice vaccinated with rLiHyD plus saponin (n = 4) were
in vitro stimulated with SLA (25 lg/mL; control) and incubated in
the absence (positive control) or presence of 5 lg/mL of
monoclonal antibodies (mAb) against mouse IL-12, CD4+ or
CD8+ (panel b). The levels of IFN-c in supernatants are shown.
(a) indicates statistically significant differences from antibody
treated samples and the untreated control sample (P < 0001).
Bars represent the mean  standard deviation (SD) of the groups.
Figure 4 Anti-Leishmania infantum SLA humoral response after
challenge. Sera samples were obtained from control and
vaccinated mice (n = 4, per group), 10 weeks after infection with
L. infantum. The levels of IgG1 and IgG2a isotypes against
L. infantum SLA are shown. Bars represent the mean  standard
deviation (SD) of the groups. (a) indicates statistically significant
increase in IgG2a levels in vaccinated group regarding the saline
and saponin groups (P < 0001). (b) indicates statistically
significant decrease in IgG1 levels between vaccinated and both
control groups (P < 0001).
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intracellular amastigotes. In an attempt to evaluate the
parasite antigen-specific activation of macrophages in the
three groups of mice, the presence of nitrite in culture
supernatants was assayed as an indicator of NO produc-
tion. For that purpose, spleen cells from infected mice
(control and vaccinated mice groups) were cultured in the
absence or in the presence of L. infantum SLA or the rLi-
HyD protein. Antigen-specific nitrite production was only
detected in supernatants of the vaccinated and protected
mice for both tested antigenic preparations (Figure 7).
DISCUSSION
In a recent immunoproteomic approach performed in sta-
tionary promastigote and axenic amastigote total extracts
of L. infantum (29), different parasite proteins recognized
by antibodies in sera of dogs suffering from active VL
were characterized. Among them, some proteins annotated
as hypothetical proteins were identified. These proteins are
usually considered to have not defined functions, as they
are predicted by genomics but they have not known
domains or enough sequence conservation with other pro-
teins (32). However, their antigenicity may be indicating
Figure 5 Vaccine-induced rLiHyD-specific cellular response.
Single spleen cells of mice that received saline or were immunized
with saponin or rLiHyD plus saponin (n = 4, per group) were
collected before and after Leishmania infantum infection, and were
nonstimulated (medium, negative control) or in vitro stimulated
with rLiHyD protein (20 lg/mL), for 48 h at 37°C in 5% CO2.
IFN-c, IL-12, GM-CSF, IL-4 and IL-10 levels were measured by
ELISA in the culture supernatants before (a) and after (b)
parasite challenge. Bars represent the mean  standard deviation
(SD) of the groups. (a) indicates statistically significant difference
in relation to the saline group (P < 0001). (b) indicates
statistically significant difference in relation to the saponin group
(P < 0001).
Figure 6 Vaccine-induced anti-rLiHyD humoral response. Sera
samples were obtained from mice that received saline or were
immunized with saponin or rLiHyD plus saponin, before (n = 4)
(a) or after Leishmania infantum infection (n = 4) (b). Bars
represent the mean  standard deviation (SD) of IgG1 and
IgG2a anti-LiHyD reactivity values from mice sera analysed in
each experimental group. (a) indicates statistically significant
difference in relation to the saline group (P < 0001). (b) indicates
statistically significant difference in relation to the saponin group
(P < 0001).
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that they are expressed in the promastigote or the amastig-
otes forms of the parasite during the active disease, and
importantly that they are interacting with the host
immune system. The LiHyD protein can be considered
within this family of Leishmania antigens. It is recognized
by sera from L. infantum-infected dogs (29), but also by
antibodies present in the sera of L. infantum-chronically
infected BALB/c mice. Interestingly, searches in the
nucleotide or protein database have revealed that this pro-
tein is only found in the Leishmania genus. One gene copy
exists in different Leishmania genomes, with identity rang-
ing from 60% to 80%, in L. major, L. braziliensis and
L. mexicana. No orthologue genes were found in the Try-
panosoma cruzi, T. brucei, T. vivax and T. congolense
annotated genomes. In this context, we have obtained the
antigen as a purified recombinant protein and its immuno-
prophylactic properties have been analysed in a murine
model of VL: BALB/c infected with L. infantum.
Although the use of murine models to test VL vaccines
presents a limitation related to the organ-specific
responses (parasites are cleared in the liver but infect
chronically the spleen) (33), BALB/c mice infected with
L. infantum or L. donovani have been widely employed
with this purpose. In this sense, we have employed the
subcutaneous challenge instead the intravenous infection,
as similar evolution of the disease is produced (34, 35),
and intravenous infection may undervalue the potential of
some vaccine candidates (36). In addition, the rLiHyD
protein has been combined with saponin, as it is an adju-
vant able to induce cellular responses that have been
employed for some canine vaccines (32, 37). Combination
of parasite antigens with cellular adjuvants has resulted in
the characterization of effective prophylactic tools against
tegumentary and VL (16, 25, 30, 38–40).
Different previous studies evaluating vaccine candidates
against leishmaniasis in murine models have showed dif-
ferent degree of success employing proteins evolutionary
conserved (16, 27, 28, 41, 42). On the other hand, hypo-
thetical proteins have emerged as interesting alternatives
for vaccine development. As an example, Martins et al.
(2013) evaluated the immunogenicity and protective effi-
cacy of an amastigote-specific L. infantum hypothetical
protein, LiHyp1, which was administered in association
with saponin in BALB/c mice challenged subcutaneously
with stationary promastigotes of L. infantum (16). The
rLiHyp1/saponin vaccine induced a specific production of
IFN-c, IL-12 and GM-CSF. Interestingly, vaccinated ani-
mals showed significant reductions in the parasitism in
organs such as liver, spleen, BM and dLNs, when com-
pared to the control groups. Similarly, rLiHyD plus sapo-
nin-based vaccine was also able to induce a Th1 response
against the hypothetical protein. This response did not
change after challenge in quality, but it was boosted as a
result of infection, as demonstrated by the higher anti-
LiHyD immunoglobulin reactivity found in mice after
challenge. The immune response elicited by the vaccine
was able to diminish parasite numbers in all the evalu-
ated organs (liver, spleen, BM and dLN). This decrease
was correlated with high changes in the immune response
elicited against the infective agent. Protected mice showed
a pro-inflammatory profile against parasite antigens,
showing an IL-12-dependent production of IFN-c,
whereas unvaccinated controls present parasite-specific
IL10- and IL-4-driven responses. It was concluded that
the induction of cellular inflammatory responses against
the LiHyD was able to change the immune response
against the parasite.
In the present study, the involvement of the CD4+ and
CD8+ T cells in the IFN-c production was evaluated using
monoclonal antibodies in the in vitro cultures, a technical
protocol previously described by us (12, 16, 24, 39) and
others (43, 44). This strategy has permitted to evaluate the
contribution of both CD4+ and CD8+ T cells in the pro-
duction of this cytokine in experimental vaccine models,
based on the block antigen presentation. Data indicated
here shown that CD4+ T cells were the main source of
IFN-c in the vaccinated and infected mice, as the in vitro
deactivation of these cells using the anti-CD4 monoclonal
antibody significantly abrogated the parasite-dependent
production of this cytokine. In agreement, CD8+ T cells
Figure 7 Leishmania-specific nitrite production after infection.
Spleen cells from mice that received saline, saponin or rLiHyD
plus saponin (n = 4, per group) and were challenged with
L. infantum were collected 10 weeks after challenge. Spleen cells
cultures were in vitro established and independently stimulated
with SLA (25 lg/mL) or rLiHyD (20 lg/mL) for 48 h at 37°C in
5% CO2. The presence of nitrite in the supernatants was analysed
by the Griess method. Bars represent the mean  standard
deviation (SD) of the level of nitrites expressed in lM. (a)
indicates statistically significant difference in relation to the saline
group (P < 0001). (b) indicates statistically significant difference
in relation to the saponin group (P < 0001).
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also contribute, although in a less extension, to the pro-
duction of parasite-specific IFN-c-mediated response.
Our results also showed that the spleen cells from pro-
tected mice produced higher levels of parasite-specific
GM-CSF than controls, a cytokine related with macrophage
activation and related to protection against different Leish-
mania species in murine models (12, 38, 45, 46). Macrophage
activation was also demonstrated by the in vitro production
of nitrites after stimulation with the recombinant protein
and total parasite extracts. According to these data, it could
be speculated a possible activation of anti-Leishmania effec-
tor mechanisms mediated by IFN-c production, as previ-
ously described by others (39, 47, 48), mainly the induction
of the synthesis of the NO effector molecule.
Visceralizing and noncuring forms of leishmaniasis have
been evaluated on extensive works in BALB/c mice, and
disease progression has been generally thought to be asso-
ciated with a Th2-type response and, in particular, with an
early and sustained production of IL-4. Indeed, elevated
levels of IL-4, IL-10 and/or IL-13 have been associated
with VL progression (49, 50). Many authors have also
related the induction of IL-4-dependent production of
IgG1 antibodies, to be associated with the disease progres-
sion due to different Leishmania species, such as L. amazo-
nensis (38, 51) and L. infantum (12, 16, 25, 39). In this
context, a high production of IL-4 could induce to high
levels of parasite-specific IgG1 isotype antibodies in the
infected animals, this being an indicator of the polariza-
tion of Th2 response. On the other hand, IFN-c has been
implicated with the switch of antibody isotype on BALB/c
mice to the IgG2a production. In consequence, high levels
of this cytokine can induce a higher production of para-
site-specific IgG2a isotype antibodies, being this humoral
response an indicator of the development of a Th1
immune response in the animals (12, 25, 30).
Recombinant protein-based vaccines, although offering
advantages in terms of safety and production costs, must
be supplemented with immune adjuvants, to improve their
immunogenicity (Cerpa-Cruz et al., 2013). This situation
has been observed in several studies that evaluate recombi-
nant proteins, also considered effective vaccine candidates
to protect against tegumentary and VL, but whose the
association of an immune adjuvant is also considered criti-
cal to vaccine efficacy (16, 25, 29, 30, 38, 40, 52). In this
context, saponins are natural glycosides derived from ster-
oid or triterpene, which exhibit distinct biological and
pharmacological activities. Notably, they can activate the
mammalian immune system, which has led to their use as
immune adjuvants in vaccines. Their unique capacity to
stimulate both the Th1 immune response and the produc-
tion of cytotoxic T cells makes the saponins ideal for use
in vaccine compositions to protect against intracellular
pathogens, as is the case of the Leishmania parasite (53,
54). Although they are considered toxic for use in humans,
due to the possibility to cause local and granulomatous
reactions, haemolysis and local pain (55); they are one of
the few products authorized to use in dogs, being the
adjuvant employed in a commercial Brazilian vaccine to
protect against canine VL, namely Leish-Tec (56).
In the present study, vaccinated mice were able to
down-regulate the Leishmania-specific IL-10-mediated
responses generated in the control nonprotected mice. The
immuno-modulatory effects of IL-10, making macro-
phages unresponsive to IFN-c, is another determinant fac-
tor for disease progression caused by viscerotropic
Leishmania species (57–59). This would imply that the
changes observed in the present work regarding the bal-
ance between IFN-c and IL-10 during infection in pro-
tected vs. nonprotected mice are particularly important for
the VL control as previously reported (60). Overall, our
results validate the possibility to employ LiHyD, a Leish-
mania-specific protein, as a vaccine candidate against VL.
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